

Human Norovirus NS3 has RNA Helicase and Chaperoning Activities

Teng-Feng Li^{1,2}, Myra Hosmillo³, Hella Schwanke³, Ting Shu^{1,2}, Zhaowei Wang^{1,2}, Lei Yin², Stephen Curry⁴, Ian G. Goodfellow³, Xi Zhou^{1,2,*}

¹ State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China

² College of Life Sciences, Wuhan University, Wuhan, Hubei, 430072, China

³ Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom

⁴ Department of Life Sciences, Imperial College London, London, SW7 2AZ, United Kingdom

* Address correspondence to Xi Zhou, Wuhan Institute of Virology, Chinese Academy of Sciences, 44 Xiaohongshan, Wuhan, Hubei, 430071, China. Phone: +86-27-87197727; Fax: +86-27-87197727; Email: zhouxi@wh.iov.cn

ABSTRACT

RNA remodeling proteins, including RNA helicases and chaperones, act to remodel RNA structures and/or protein-RNA interactions, and are required for all processes involving RNAs. Although many viruses encode RNA helicases and chaperones, their *in vitro* activities and their roles in infected cells largely remain elusive. Noroviruses are a diverse group of positive-stranded RNA viruses in the family *Caliciviridae*, and constitute a significant and potentially fatal threat to human health. Here we report that protein NS3 encoded by human norovirus has both ATP-dependent RNA helicase activity that unwinds RNA helices and ATP-independent RNA chaperoning activity that can remodel structured RNAs and facilitate strand-annealing. Moreover, NS3 can facilitate viral RNA synthesis *in vitro* by noroviral polymerase. NS3 may therefore play an important role in norovirus RNA replication. Lastly, we demonstrate that the RNA remodeling activity of NS3 is inhibited by guanidine hydrochloride, an FDA-approved compound and, more importantly, that it reduces the replication of norovirus replicon in cultured human cells. Altogether, these findings are the first to demonstrate the presence of RNA remodeling activities encoded by *Caliciviridae*, and highlight the functional significance of NS3 in noroviral life cycle.

IMPORTANCE

Noroviruses are a diverse group of positive-stranded RNA viruses, which annually cause hundreds of millions of human infections and over 200,000 deaths worldwide. For RNA viruses, cellular or virus-encoded RNA helicases and/or chaperones have long been considered to play pivotal roles in viral life cycles. However, neither RNA helicase nor chaperoning activity has been demonstrated to associate with any norovirus-encoded proteins, and it is also unknown whether norovirus replication requires the participation of any viral or cellular RNA helicases/chaperones. We found that a norovirus protein NS3 not only has ATP-dependent helicase activity, but also acts as an ATP-independent RNA chaperone. And NS3 can facilitate *in vitro* viral RNA synthesis, suggesting the important role of NS3 in norovirus replication. Moreover, NS3 activities can be inhibited by an FDA-approved compound, which also suppresses norovirus replicon replication in human cells, raising the possibility that NS3 could be a target for anti-noroviral drug development.

INTRODUCTION

Noroviruses are a genetically diverse group of non-enveloped, positive-stranded RNA viruses belonging to genus *Norovirus* of the family *Caliciviridae*. They are further segregated into seven genogroups (GI-GVII), three of which cause diseases exclusively in humans (GI, GII, and GIV) (14, 56, 64). Human noroviruses (HuNoVs) are now considered the leading cause of viral gastroenteritis in humans across the globe. HuNoV infections are estimated to cause 684 million of cases of diarrheal disease, 1.1 million hospitalizations and 212 000 deaths worldwide, with an economic burden of ~60 billion dollars per year [8, 9]. They are highly contagious, infecting people of all ages, with higher incidence in young children and low-income settings [8, 9]. Although HuNoV infections are usually acute and self-limiting with low mortality, they often cause chronic or life-threatening infections and symptoms in immunocompromised patients and the elderly (23). As a result of their high infectivity, stability and resistance to common sanitizers, HuNoV has also been classified as Category B biodefense agents (23, 30). However, despite its substantial burden and potential threat,

there is still no vaccines or antiviral drugs available to prevent or treat norovirus infection (2, 24, 25).

The noroviral genomic RNA is 7.4-7.7 kb in length and typically organized into three open reading frames (ORF1-3) (24). Exceptionally, the GV murine norovirus (MNV) has an additional ORF (ORF4) encoded within ORF2 (40, 54). The 5' proximal ORF1 encodes a large polyprotein that is cleaved by a norovirus-encoded protease (NS6^{Pro}) into at least six mature nonstructural proteins, while the 3' proximal region of noroviral genomic RNA is transcribed into a subgenomic RNA that contains ORF2 and ORF3 that encode the major and minor structural proteins VP1 and VP2, respectively (Fig. 1A). Although these viruses have been extensively studied for decades, our understanding about the mechanisms of the nonstructural proteins involved in noroviral replication is very limited, particularly in comparison to other positive-stranded RNA viruses such as picornaviruses and flaviviruses.

For many RNA viruses, the viral RNA (vRNA) contains multiple *cis*-acting elements that play pivotal roles in vRNA replication, translation and encapsidation, during the viral life cycle (1, 18, 39). As with cellular RNA molecules, these elements are often highly structured in vRNAs and must be folded into the correct tertiary structures to be functional. However, this can be problematic because RNAs can be easily trapped in stable but misfolded intermediate states (3, 19). To avoid this, cells and viruses encode a variety of RNA remodeling proteins, such as RNA helicases and RNA chaperones, which can destabilize RNA-RNA or RNA-DNA duplexes to promote the proper folding or re-folding of RNAs (17, 37, 47). In addition, viral or cellular RNA helicases are thought to participate the unwinding of viral replicative intermediate double-stranded RNAs (vRI-dsRNAs) formed during vRNA replication, thereby allowing recycling of vRNA templates for further rounds of vRNA synthesis. RNA helicases have nucleoside triphosphatase (NTPase) activity, using the energy of NTP binding and/or hydrolysis to unwind RNA duplexes, and are believed to participate in most ATP-dependent rearrangement of structured RNAs (20). RNA chaperones are a heterogeneous group of proteins that can destabilize RNA duplexes and promote correct RNA folding in an ATP-independent fashion (41). A wide range of RNA viruses, including flavivirus (15), picornavirus (59), alphavirus (22), coronavirus (29), reovirus (60), iflavirus (9), and alphetetravirus (57) have been found to encode their own RNA helicases and/or RNA chaperones (61).

Sequence analysis showed that the norovirus NS3 protein, also known as p41, contains signature motifs that are conserved in superfamily-3 (SF3) viral helicases such as the human enterovirus 2C^{ATPase} (EV71 2C^{ATPase}) (59), simian virus 40 (SV40) large T antigen (LTag) (31), adeno-associated virus 2 (AAV2) Rep40 (10, 63), and the human papillomavirus 18 (HPV18) E1 protein (32) (Fig. 1). Consistent with this observation, the NS3 protein encoded by Southampton virus (SHV), a GI HuNoV, has been shown to have a NTPase activity (45). In addition, norovirus NS3 has been recently reported to associate with vRI-dsRNAs in viral replication complex (vRC) and to induce vesicular structures (4, 11, 13). However, previous work has yet to demonstrate RNA helicase or chaperoning activity associated with NS3 or any other norovirus- or calicivirus-encoded proteins, or that the replication of norovirus or calicivirus requires the participation of any viral or host RNA remodeling activities. This gap hampers our understanding about the replication mechanisms of this large group of medically important human pathogens, as well as the development of anti-noroviral drugs that may specifically target viral RNA helicase/chaperoning activities.

Our previous work on enterovirus 2C^{ATPase} revealed that, *in vitro*, 2C^{ATPase} has RNA remodeling activity when expressed using a baculovirus-based expression system (59). Here, we show that NS3

encoded by Norwalk virus (NV; genotype GI.1 HuNoV), the prototype strain of the genus *Norovirus*, also has NTP-dependent RNA helicase activity. Moreover, we demonstrate that NS3 can also act as an RNA chaperone that is able to remodel structured RNAs and facilitate strand annealing independently of NTP. We have also found that NS3 can facilitate the *in vitro* synthesis of vRNA by NV NS7/RNA-dependent RNA polymerase (RdRP) on the 3' antigenomic template, suggesting that NS3 plays important role in noroviral RNA replication. Additionally, we have demonstrated that the guanidine hydrochloride (GuHCl), which is a U.S. FDA-approved small molecule drug and a well-known inhibitor of poliovirus 2C^{ATPase}, is able to inhibit the RNA helicase activity of NS3 in a dose-dependent manner. More importantly, GuHCl has been further determined to inhibit the replication of NV replicon in cultured human cells, which highlights the functional significance of NS3 in noroviral life cycle.

RESULTS

NV NS3 shares similar consensus motifs and structure with other SF3 viral helicases

A comparison of the amino acid sequence of NV NS3 with members of the SF3 viral helicases, including EV71 2C^{ATPase}, AAV2 Rep40, SV40 LTag, and HPV18 E1, revealed that NV NS3 contains the conserved SF3 helicase A, B, and C motifs (Fig. 1B).

Since the three-dimensional (3D) structure of noroviral NS3 has not yet been reported, we modeled the NV NS3 structure using the ROBETTA server for protein structure prediction and analysis (5). The predicted model of the NV NS3 revealed that the C-terminal two thirds consisting of amino acids (a.a) at positions 122-363 (i.e. NS3 Δ N) is comprised of two structurally independent domains; a helicase core (HC; a.a. 122-288) forming a central five-stranded β -sheet sandwiched by α helices on both sides, and the C-terminal domain (CTD; a.a. 289-363) comprising of several α helices. These domains are linked by flexible loops (Fig. 1C), and interestingly, demonstrates some limited similarity with the counterpart region of EV71 2C^{ATPase} (59). Moreover, the predicted SF3 motifs A, B, and C of NV NS3 are nicely overlapped with the conserved SF3 motifs in these other SF3 viral helicases (Fig. 1D-F).

NV NS3 contains NTPase activity

Previous studies by Pfister and Wimmer found that bacterially expressed Southampton virus (SHV) NS3 has NTPase activity (45). To confirm whether NV NS3 also has this activity, we expressed recombinant Maltose binding protein (MBP)-fusion NV NS3 using a baculovirus expression system, and then examined the NTPase activity by incubating MBP-NS3 with different NTPs. The hydrolysis of NTP was measured using a sensitive colorimetric assay that determines the total amount of released inorganic phosphate. As found for SHV NS3, our data showed that NV NS3 hydrolyzed all four types of NTPs (Fig. 2A). However, although SHV NS3 was reported to hydrolyze UTP less well than ATP (45), NV NS3 exhibited similar efficiency in the hydrolysis of these NTPs (Fig. 2A).

To further characterize the NTPase activity of NV NS3, we assessed the ATPase activity of MBP-NS3 under different of ATP and Mg²⁺ concentrations as well as at different pH, as ATP is the major energy source in cells. Our results showed that the amount of hydrolyzed ATP was increased

with increasing amounts of ATP (Fig. 2B). In addition, our data indicates that the ATPase activity of MBP-NS3 is Mg^{2+} -dependent, since its ATP hydrolyzing activity was undetectable in absence of Mg^{2+} . Whilst the ATPase activity of MBP-NS3 was found to be optimal at 2 mM Mg^{2+} concentration, higher levels of Mg^{2+} inhibited the ATPase activity (Fig. 2C). The optimal pH for MBP-NS3 ATPase activity was found to be ~pH 7.6, but broad activity was maintained between pH 6.8 and pH 8.0 (Fig. 2D).

We also expressed MBP-fusion NV NS3 using *E. coli*, and examined its NTPase activity. We confirmed that the bacterially expressed MBP-NS3_{NV} can also hydrolyze ATP and other NTPs and shows similar biochemical properties with the eukaryotically expressed MBP-NS3_{NV} (data not show). Altogether, our data demonstrate that similar to SHV NS3, the NV NS3 has an NTPase activity that hydrolyzes all four NTPs and is Mg^{2+} -dependent.

NV NS3 has nucleic acid helix unwinding activity

To assess the potential helix unwinding activity of NV NS3, we annealed a short hexachloro fluorescein (HEX)-labeled RNA and a longer unlabeled RNA to generate a standard RNA helix substrate with both 5'- and 3'-single stranded protrusions (Fig. 3A and Table 1). The helix unwinding assay was performed by incubating the standard RNA helix substrate with purified MBP-NS3 in the standard unwinding reaction and then the substrate was evaluated via gel electrophoresis. As shown in Fig. 3A, the HEX-labeled RNA strand was released from the RNA helix substrate in the presence of MBP-NS3, whereas the RNA helix substrate remained annealed when MBP alone was added as a mock helicase, showing that NV NS3 can unwind the RNA helix. The reactions were performed in the presence of ATP and $MgCl_2$. The boiled helix substrate or the addition of MBP-fusion EV71 2C^{ATPase} were used here and in subsequent experiments as relevant controls for helix unwinding activity.

Because some viral RNA helicases have been reported to unwind DNA helices or RNA-DNA hybrids (59), we sought to examine if NV NS3 can unwind nucleic acid helices containing DNA. For this purpose, we constructed three helix substrates: a DNA duplex (D*/D; Fig. 3B), an RNA-DNA hybrid with a longer unlabeled RNA (D*/R; Fig. 3C) or DNA strand (R*/D; Fig. 3D). Each helix substrate was reacted with MBP-NS3 under the same condition as in Fig. 3A, and our results showed that NV NS3 can efficiently unwind either of the RNA-DNA hybrids (Fig. 3C and 3D), but unwound the DNA duplexes less effectively (Fig. 3B).

We further evaluated the RNA helix unwinding activity of MBP-NS3 under different conditions. We observed that the helix unwinding activity of MBP-NS3 can be promoted by the presence of NTP, particularly ATP or GTP (Fig. 4B), indicating that NV NS3 has an RNA helicase activity. Consistent with the characterization of NS3 NTPase activity (Fig. 2C and D), the optimized helix unwinding activity of MBP-NS3 was found around 2 mM Mg^{2+} (Fig. 4C) at pH value of around 7.6 (Fig. 4D). Collectively, these findings suggest that the NV NS3 has an NTP-dependent nucleic acid helix unwinding activity.

NV NS3 directs the RNA helix unwinding from both 5'→3' and 3'→5' directions

The directionality of helix unwinding is a fundamental characteristic of helicases (20). Previous

studies of other SF3 viral helicases have revealed that the helicase activity of EV71 2C^{ATPase} has a 3'→5' directionality, while AAV2 Rep40 and HPV18 E1 unwind helices bidirectionally (10, 32, 59). To determine the unwinding directionality of NV NS3, we generated two different RNA helix substrates: one containing a 5' single-stranded protrusion (Fig. 5A), and the other with a 3' single-stranded protrusion (Fig. 5B). Each substrate was subjected to helix unwinding assay in the presence of MBP-NS3. Our data showed that RNA helix substrates with either a 5'- or a 3'-protrusion could be unwound by MBP-NS3 (Fig. 5C). Moreover, the unwinding of either substrate by MBP-NS3 can be promoted by the presence of ATP in a dose-dependent manner (Fig. 5D and E). Based on these observations, we conclude that NV NS3 directs the unwinding of RNA helix from both 5'→3' and 3'→5' directions in an ATP-dependent manner, similar to AAV2 Rep40, another SF3 viral helicase (10, 32, 59).

The conserved SF3 motif A is critical for the helicase activity of NS3

The sequence analysis of NS3 indicates that NS3 contains consensus motifs that are characteristic of SF3 viral helicases (Fig. 1). The motif A has been recognized as a core element of the NTP binding and NTPase active site of SF3 helicases (20) and is conserved in different noroviruses (Fig. 6A). Previous work by Pfister *et al.* has shown that the mutation of motif A in SHV NS3 almost completely eliminated its ATPase activity (45). Moreover, motif B of SF3 helicases has been reported to chelates Mg²⁺ (20). We wanted to investigate if the conserved SF3 motif A or B is important for the helicase activity associated with norovirus NS3. To this end, we generated the GK168AA and GK168AA-DD212AA mutants of MBP-fusion NS3 (MBP-NS3_{GK168AA} and MBP-NS3_{GK168AA-DD212AA}) and expressed the proteins using the baculovirus expression system. In our standard helix unwinding assays we found that both of the GK168AA and GK168AA-DD212AA mutations dramatically reduced the helix unwinding activity of NS3 compared to wild-type (Fig. 6B). Moreover, the addition of increasing concentrations of ATP had very little effect on helix unwinding by MBP-NS3_{GK168AA} (Fig. 6C). These findings determine that the conserved SF3 motifs are critical for the helicase activity of NS3.

NV NS3 also possesses an NTP-independent RNA chaperoning activity

Although we have determined that NV NS3 requires NTP to reach its optimal helix unwinding activity (Fig. 4B, 5D, and 5E) and that the conserved SF3 motif A is critical for its helicase activity (Fig. 6), we found that a portion of the helical RNA substrate could still be unwound by MBP-NS3 in the absence of ATP (Fig. 4B, 5D, and 5E). To confirm these observations and exclude the possible interference of trace amounts of NTP in the unwinding assays, we alternatively used AMP-PNP, an ATP analog that is non-hydrolysable and able to block NTPase activity. The incorporation of 5 mM AMP-PNP, instead of ATP or other NTPs, did not completely abolish the RNA helix unwinding by MBP-NS3 (Fig. 7A). Whilst both the RNA helicases and RNA chaperones possess RNA remodeling activities, and the fundamental difference between them is that the former activity requires the participation of NTP, whereas the latter is NTP-independent (41). These observations therefore suggest that NV NS3 also contains an NTP-independent RNA chaperoning activity.

RNA chaperones are generally thought to destabilize misfolded RNA secondary structures to facilitate the re-formation of more stable RNA structures (19). To further characterize the RNA

chaperoning activity of NV NS3, we adapted a canonical assay, which evaluates the helix-destabilizing and annealing acceleration activities of RNA chaperones (12). In this assay, we designed and generated two 42-nt complementary RNA strands, each of which forms a defined stem-loop secondary structure; in addition, one strand is 5'-HEX labeled and the other is unlabeled, as indicated in Fig. 7B. Equal amounts of the two strands were mixed and incubated in the presence or absence of MBP-NS3, and the hybridization of the two strands were then determined using gel shift assay. In these reactions, ATP or other NTPs were not supplemented. Our data showed that the levels of the annealed hybrids were gradually increased with the increasing amounts of MBP-NS3 (Fig. 7C). Moreover, although minimal spontaneous hybridization could be observed in the absence of MBP-NS3 with prolonged incubation time (Fig. 7D, lanes 3-6), the addition of MBP-NS3 further enhanced the hybridization at each time points (Fig. 7D, lanes 7-10). Altogether, our results show that NV NS3 can destabilize structured RNAs and facilitate the formation of a more stable RNA structure, confirming that NV NS3 is also a NTP-independent RNA chaperone.

NV NS3 promotes noroviral RNA synthesis *in vitro*

For positive-stranded RNA viruses, their RdRP-mediated vRNA replications generate viral replicative intermediate double-stranded RNAs that could be unwound by RNA helicases in order to recycle vRNA templates (28). Virus-encoded RNA chaperones may help rearrange the structured RNA elements of vRNA templates, thereby facilitating vRNA synthesis (60). After determining the RNA helicase and chaperoning activities of NV NS3, we wanted to evaluate the potential role of NS3 in noroviral RNA replication. As illustrated in Fig. 8A, we incubated a recombinantly purified MBP-fusion HuNoV NS7/RdRP protein with *in vitro* transcribed RNA corresponding to the 400 nts at the 3'-end of HuNoV antigenomic (-)-vRNA, which is presumably the template for the initiation of (+)-vRNA synthesis, in the presence or absence of WT or GK168AA mutant MBP-NS3. The reaction was not supplemented with an oligonucleotide RNA primer as norovirus RNA synthesis can occur primer-independently, at least *in vitro* (16). And the newly synthesized RNA was detected by Northern blots using the probe specific for (+)-vRNA. Here, we observed that the presence of WT MBP-NS3 promoted the NS7/RdRP-mediated production of (+)-vRNA strands from the (-)-vRNA templates, and that the promoting effect of NS3 could be further enhanced with increasing the reaction time (Fig. 8B and 8C). On the other hand, the motif A mutation mostly eliminated the promoting effect of MBP-NS3 on *in vitro* RNA synthesis (Fig. 8D and 8E).

GuHCl inhibits the NTPase and RNA helix unwinding activities of NV NS3

Previous studies have reported that the NTPase and RNA helicase activities of enterovirus 2C^{ATPase} can be inhibited by GuHCl (6, 34, 35, 44, 46, 59), which also inhibits replication of vRNA of a number of enteroviruses (38, 53). Given the similarity between the consensus motifs in enterovirus 2C^{ATPase} and norovirus NS3, we wanted to examine whether NV NS3 could also be a target for guanidine inhibition. NTPase assays showed that GuHCl inhibited the ATPase activity of NV NS3 in a dose-dependent manner (Fig. 9A). This result is in contrast with the previous observation by Pfister and Wimmer who demonstrated that even in the presence of up to 10 mM GuHCl, the ATPase activity of SHV NS3 was not inhibited (45). This contrasting results might be due to the different expression strategies (eukaryotic vs. prokaryotic) or the inherent biochemical

properties of two NS3 proteins, which were also shown to have different hydrolysis preferences for UTP (Fig. 2A) and different responses to Mg^{2+} concentrations higher than 2 mM (Fig. 2C).

To examine if GuHCl could also inhibit the helix unwinding by NV NS3, the helix unwinding reactions were performed in the presence of NS3 and increasing concentrations of GuHCl. Our results showed that the presence of GuHCl inhibited the helix unwinding by NS3 in a dose-dependent manner (Fig. 9B and C). Intriguingly, we examined the effect of GuHCl on the RNA chaperoning activity of NV NS3 using the RNA strand hybridization assay. Our data showed that the addition of GuHCl at different concentrations had no obvious effect on NS3 RNA chaperoning activity (Fig. 9D).

It is important to note that the helicase activity and ATPase activity show similar sensitivities to GuHCl, and the inhibitory effects due to GuHCl on helicase and ATPase activities of NV NS3 are moderate, but similar to the effects observed in EV71 2C^{ATPase} (59). Nevertheless, these data demonstrate that GuHCl is an inhibitor of the key biochemical activities of NV NS3.

GuHCl inhibits NV replication in cultured human cells

Whilst we have shown that GuHCl can inhibit the NTPase and helix unwinding activities of NV NS3, we sought to determine whether GuHCl treatment can inhibit HuNoV replication in cells. To this end, the effect of GuHCl on HuNoV replication was evaluated by using the NV replicon system in cultured human gastric tumor (HGT-1) cells. The levels of NV RNA in the presence of GuHCl at different concentrations were determined by real-time quantitative reverse transcription-PCR (qRT-PCR), and the expression levels of NV proteins were determined by western blotting of NV NS3. 2'-C-methylcytidine (2CMC), a nucleoside analog that has been reported to inhibit HuNoV replication (49, 50), was used as the positive control. As shown in Fig. 9E, the presence of 1.125 mM GuHCl significantly reduced the level of NV RNA to around 50% of that under mock treatment, while increasing the GuHCl concentration to 3.25 mM only moderately enhanced the inhibitory effect of GuHCl to NV RNA replication. As expected, 2CMC showed a strong inhibitory effect on NV RNA replication (Fig. 9E). We also showed that the presence of 1.125 or 3.25 mM GuHCl did not affect the viability of HGT-1 cells, as found for 2CMC treated cells, excluding the possibility that the inhibitory effect of GuHCl on NV RNA replication was due to inducing cell death (Fig. 9F). Hence, GuHCl can inhibit the replication of NV replicon at 1.125 mM in cultured human cells without apparent cytotoxicity.

DISCUSSION

During the life cycle of RNA viruses, cellular or virus-encoded RNA helicases or chaperones are believed to facilitate correct folding or unfolding of RNA structures or to separate vRI-dsRNAs for more rounds of vRNA replication (3, 19, 59). Here we report for the first time that NV-encoded NS3 has both NTP-dependent RNA helicase and NTP-independent RNA chaperoning activities that can unwind RNA helices, and destabilize and remodel structured RNA molecules. Moreover, we have found that NS3 can stimulate NS7/RdRP-mediated noroviral RNA synthesis *in vitro*, suggesting that NS3 plays an important role in noroviral RNA replication. Our work has also shown that GuHCl, an FDA-approved small molecule drug, can inhibit the RNA helicase activity of NS3 *in vitro*, and more

importantly, that this small molecule has some inhibitory activity against replication of a HuNoV replicon in cultured human cells.

The RNA remodeling activities of viral proteins are generally believed to play important roles in viral life cycles (65). For instance, during vRNA replication of RNA viruses, vRI-dsRNAs must be efficiently unwound, thereby releasing nascently synthesized progeny vRNAs from vRNA templates. Moreover, viral genomic and antigenomic RNAs contain multiple *cis*-acting elements, highly structured RNA regions that usually play pivotal roles in the replication, translation, and encapsidation of vRNAs (1, 36). Sometimes, a specific RNA structure required for one vRNA function, like translation or encapsidation, may need disruption and refolding to facilitate another vRNA function, like vRNA replication, and vice versa. For example, genomic RNAs or mRNAs of some RNA viruses, including norovirus (33, 39, 62), flavivirus (18), hantavirus (48), and reovirus (55), can undergo circularization, resulting in the base-pairing of vRNA 5'- and 3'-ends to form panhandle-like structures that may facilitate vRNA translation, encapsidation, or RdRP recruitment to 3'-end of vRNAs (8, 36). However, for initiation of RNA replication, these cyclized vRNA structures need to be disrupted to make the 3'-end of vRNAs accessible by RdRPs; an example of this type of activity is the chaperoning effect of cypovirus VP5 on cyclized cypoviral mRNAs (60). Viral RNA remodeling proteins may also dynamically facilitate proper folding and unfolding of different vRNA structures, thereby allowing vRNAs to switch among distinct functionalities.

For noroviruses, it has been found that their vRNAs contain multiple *cis*-acting elements and RNA secondary structures, which are important for noroviral replication (33, 36, 39, 62). With that in mind it is intriguing that we have observed ability of NS3 to enhance NS7/RdRP-mediated noroviral RNA synthesis *in vitro*, particularly since noroviral NS3 has recently been found to associate with vRI-dsRNAs in vRC on intracellular membranes (4, 11, 13). These findings indicate the critical roles of NS3 in noroviral RNA replication. However, owing to technical limitations, the RNA remodeling activities of viral proteins have been mainly studied *in vitro*, and it is difficult to imagine how the regulation of the structures and functions of vRNAs by viral RNA helicases/chaperones can be investigated in detail in virus-infected cells. Future advances in techniques may overcome these barriers and help understand the mechanism(s) of how the RNA helicase/chaperoning activities of NS3 remodel vRNAs at different stages of noroviral life cycle.

Interestingly, we found that the guanidine salt, GuHCl, inhibits both the ATPase and RNA helix unwinding activities of NV NS3 in a dose-dependent manner (Fig. 9), similar to the effects of the same compound on enterovirus 2C^{ATPase} (44, 59). Although previous work found that the ATPase activity of SHV NS3 was not inhibited by GuHCl (45), our data show that NV NS3 has some difference with SHV NS3 in terms of ATPase activity. For example, while SHV NS3 has been found to hydrolyze UTP much less well than ATP (30), NV NS3 exhibited similar hydrolysis efficiency to both ATP and UTP (Fig. 2A). Moreover, when the concentration of Mg²⁺ is higher than 2 mM, the ATPase activity of NV NS3 was inhibited in a dose-dependent manner (Fig. 2C), while that of SHV NS3 was moderately enhanced (30). It is possible that the difference between NV NS3 and SHV NS3 in ATPase activity is due to the different (eukaryotic vs. prokaryotic) expression strategies.

Virus-encoded RNA remodeling proteins, particularly helicases, have long been considered as valuable targets for antiviral compounds, because they are well conserved within or even across virus families (26). In particular, enterovirus 2C^{ATPase}, another SF3 viral RNA helicase, has been found to be inhibited by ~1 mM GuHCl, as is enterovirus replication (6, 34, 35, 46, 59). Using a NV replicon

as model, our studies demonstrate that ~1 mM GuHCl can significantly inhibit the replication of HuNoV in cultured human cells with negligible cell toxicity (Fig. 9). Similarly, GuHCl can inhibit the replication of poliovirus at the same concentration (59). Guanidines are ubiquitously present in nature, and are categorized as organic superbases with highly basic nature and notable stability, that can function as mediators of specific non-covalent binding in various catalytic processes (51, 52). Due to their physicochemical characteristics, guanidine molecules probably bind stably to the surfaces of viral RNA remodeling proteins, such as enterovirus 2C^{ATPase} and HuNoV NS3, and may therefore alter their conformations, electrostatic states, and/or protein-protein/RNA interactions, thereby inhibiting their RNA remodeling activities. In accordance with this idea, high concentrations of Mg²⁺ (> 2mM) have been found to inhibit the helix unwinding by either NV NS3 (Fig. 2C) or EV71 2C^{ATPase} (59). GuHCl is a U.S. FDA-approved small compound drug that has been used to treat the symptoms of muscle weakness and fatigability associated with Eaton-Lambert syndrome (<http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=001546>) (42, 43). Moreover, guanidine derivatives have attracted widespread interest for developing drugs against various diseases, and some of them have been found to be potential antivirals against hepatitis C virus (HCV), human immunodeficiency virus (HIV), and flaviviruses (15, 51, 52). It is unlikely that GuHCl can be directly used as an antiviral drug against HuNoV infection due to the high concentration needed for inhibition of NS3 and NV replication. However, given the presence of multiple derivative forms of guanidine, the syntheses and screening of various guanidine derivatives and guanidine-containing compounds may help in the quest for small molecules that have better inhibitory effects on HuNoV NS3 and HuNoV replication.

In conclusion, this study provides the first demonstration of the RNA helicase and chaperoning activities associated with a norovirus- or calicivirus-encoded protein, and reveals that NS3 may have a direct function (in concert with the NS7/RdRP) in norovirus RNA replication. Moreover, it also provides evidence that GuHCl is an inhibitor of not only the *in vitro* RNA remodeling activities of NS3 but also the replication of HuNoV in human cells. Altogether, these findings highlight the functional significance of NS3 in noroviral life cycle, and shed new light on the understanding of norovirus replication.

MATERIALS AND METHODS

Construction of recombinant baculoviruses, and expression and purification of recombinant proteins

The generation of pFastBac HTB-MBP has been described previously (9). The cDNA of NV NS3 (GenBank Accession No. KF039736) was synthesized by Tian Yi Hui Yuan Biotech Co. (Wuhan, China), and cloned into the vector pFastBac HTB-MBP. Site-directed mutagenesis was conducted as previously described (9). The resulting plasmids were subjected to Bac-to-Bac baculovirus system to produce recombinant proteins. The primers used for NS3 plasmid construction: forward-GAATTCATGGGCCCCGAGGACCTTGCCAGGGATCTCGTG and reverse-GTCGACCTACTGGAGTTGGAACCTCATCCTGTCTCTCCAT; the primers for the GK168AA and GK168AA-DD212AA of NS3 are: forward-TGTGGGCCCCC TGGTATAGCTGCTACCAAG and reverse-GTTCTGCTGCCTTGGTAGCAGCTAT ACCAG; forward-GCTGTGGGCTGCTTATGGAATGACAAAGAT and reverse-TG

TATCTTTGTCATTCCATAAGCAGCCCAC.

The expression and purification of recombinant MBP alone and MBP-fusion proteins were conducted using standard procedures as previously described (9, 60). All purified proteins were quantified by BCA Protein Assay Kit (CWBIO, China) and stored at -80°C in aliquots. Proteins were separated on 10% SDS-PAGE and visualized by Coomassie blue.

Structural modeling and structural alignment analyses

The 3D structure of NV NS3 was modeled by submitting its amino acid sequence to the HMMSTR/Rosetta server [from Robetta, University of Washington (<http://robetta.bakerlab.org/>)]. Five models were obtained, and the best one was chosen as a template based on its score, and assessed by submitting it to the SWISS-MODEL Server [from Swiss Institute of Bioinformatics and the Biozentrum, University of Basel, Switzerland (<http://siwssmodel.expasy.org>)]. The Figure of the modeled NS3 Δ N and the structural alignments with SV40 LTag (PDB ID code 4GDF), HPV18 E1 (PDB ID code 1TUE), and AAV2 Rep40 (PDB ID code 1U0J) were generated from coordinate files using PyMOL version 1.1 (DeLano Scientific LLC, Southern San Francisco, CA).

NTPase assay

NTPase activities were determined via measuring the released inorganic phosphate during NTP hydrolysis using a direct colorimetric assay according to our standard procedures as previously described (9). The concentrations of released inorganic phosphate were determined by matching the A620 in a known inorganic phosphate curve. All of the results given with this quantitative assay were averages of three independently repeated experiments.

Preparation of oligonucleotide helix substrates

The nucleic acid helix substrates were prepared according to our standard procedures as previously described (59). In brief, RNA, DNA or RNA-DNA hybrid helix substrates were prepared by annealing two complementary nucleic acid strands, of which one strand was labeled at 5'-end with HEX, while the other was unlabeled. The two strands were mixed at a proper ratio in a 10 μ L reaction mixture containing 25mM HEPES-KOH (pH 8.0) and 25mM NaCl. And the mixture was then heated to 95°C for 5 min and gradually cooled to 25°C to produce helical duplexes. All HEX-labeled DNA and RNA strands were purchased from Takara (Dalian, China), unlabeled DNA strands were synthesized by Invitrogen, and unlabeled RNA strands were *in vitro* transcribed using T7 RNA polymerase (Promega, Madison, WI). The *in vitro* transcribed RNA strands were purified by Poly-Gel RNA Extraction Kit (Omega bio-tek, Guangzhou, China) according to the manufacturer's instructions. The standard RNA helix substrate with both 5' and 3' protrusion was annealed using RNA1 and RNA2, the DNA helix substrate was annealed using DNA2 and DNA3, the RNA*-DNA hybrids was annealed using RNA1 and DNA1, the DNA*-RNA hybrids was annealed using DNA1 and RNA3, the 3' protruded RNA helix was annealed using RNA1 and RNA4, and the 5' protruded RNA helix was annealed using RNA1 and RNA5. All oligonucleotides used in this study are listed in Table 1.

Table 1. List of oligonucleotides.

Oligonucleotide	Sequence(5'-3')
RNA1	*CAUUAUCGGAUAGUGGAACCUAGCUUCGACUAUCGGAUAAUC
RNA2	AAUAAAGAUUAUCCGAUAGUCGAAGCUAGGUUCCACUAUCCGAUA AUGAAAUAA
RNA3	UGUAGUGCUGCCAUGGUGUGGUGGUGGUGGUUGUGGUGGAGCUAC GAAC
RNA4	GAUUAUCCGAUAGUCGAAGCUAGGUUCCACUAUCCGAUAAUGAAA UAA
RNA5	AAUAAAGAUUAUCCGAUAGUCGAAGCUAGGUUCCACUAUCCGAUA AUG
DNA1	AATAAAGATTATCCGATAGTCGAAGCTAGGTTCCACTATCCGATAATGA AATAA
DNA2	*CACCACAACCACCACCACCATGG
DNA3	TGTAGTGCTGCCATGGTGTGGTGGTGGTGGTGGTGGTGGAGCTACGA AC
Probe	GUGAAUGAAGAUGGCGUCUAACGGCGCUUCCGCUGCCGCUGUUGC CAACAGCAACAACGACAUCGCAAAAUCUUCAAGUGACGGUGUGUU UUCUAACAUGGCGUCACUUUUAAAGCGGGCCUCGGGGCG CGGCCUAAAC

*indicate HEX labeled strand.

Helix unwinding and RNA strand hybridization assays

Helix unwinding assay was performed according to our standard procedures as previously described (60). The reaction mixtures were electrophoresed on 15% native-PAGE gels and then scanned with a Typhoon 9500 imager (GE Healthcare, Piscataway, NJ).

The RNA hybridization assay was carried out according to our standard procedures as previously described (60). In brief, the indicated amount of protein, 0.2 pmol HEX-labeled stem-loop-structured RNA strand, and 0.2 pmol unlabeled stem-loop-structured RNA strand were added to reaction buffer and incubated for 1 h or the indicated time. The sequences of the stem-loop-structured RNA strands are given in Fig. 7B. The reaction products were resolved on 15% native-PAGE gels, followed by scanning by Typhoon 9500 imager (GE Healthcare, Piscataway, NJ).

In vitro RdRP assays

The vRNA template was *in vitro* transcribed by T7 RNA polymerase as described above. The (-)-vRNA template contains 1-400 nts of 3'-end HuNoV (-)-RNA, which is complementary to 5'-end

400 nts of HuNoV (+)-RNA. The transcribed product was purified by Poly-Gel RNA Extraction Kit (Omega bio-tek, Guangzhou, China) according to the manufacturer's instruction. The cDNA of HuNoV NS7/RdRP (GenBank Accession No. KR904238) was amplified by PCR from full-length GII.4-Sydney HuNoV cDNA, which was generously provided by Dr. Linqing Zhao (Capital Institute of Pediatrics, Beijing, China), and cloned into the vector the vector pMAL-c2X-MBP (primers: forward-GGATCCATGGGAGGAAACACTGTCATATG TGCCACCCAG and reverse-GTCGACTCACTCGACGCCATCTTCATTCACAAA ACTGGG). The recombinant MBP-fusion NS7/RdRP was purified as described above. The RdRP assay was performed as previously described with minor modification. In brief, indicated amounts of MBP-NS3 were included in 10 µl reactions containing 50mM HEPES-KOH (pH7.5), 12.5mM KCl, 5mM MgCl₂, 5mM DTT, 20U RNasin (Promega), and 5mM NTPs. MBP-NS3 was included in the reaction mix with or without 10 pmol NS7/RdRP at 30°C for the indicated time. After that, the reaction was terminated by 2×loading buffer (20% 10×MOPS running buffer, 10% glycerol, 50% formamide, 20% formaldehyde and 0.05% bromophenol blue), and then denatured at 65°C for 10min. The samples were electrophoresed on 1.5% agarose-formaldehyde denaturing gels, and transferred onto N+ nylon membranes (Roche). The RdRP products were detected via Northern blots that were performed according to our standard procedures (58). The probe for Northern blots was listed in Table 1.

Assessment of GuHCl treatment in HuNoV-replicon harboring cells

A baby hamster kidney cell line harbouring the NV replicon, provided by Dr. Kim Green (National Institutes of Health, Bethesda, MD), was used as a source of viral VPg-linked RNA (7). Total RNA was isolated from the BHK-NV replicon containing cell line and transfected into HGT-1 (27). The transfected cells were placed under selection using 1mg/ml of G418 and clonal populations were generated by limiting dilution. The levels of viral RNA determined by qRT-PCR as described and a single clone selected for future use, referred to as HGT-NV.

To examine the effect of GuHCl on NV replication, HGT-NV cells were seeded in 96-well plate at 1,000 cells per well without G418. HGT-NV cells were immediately incubated with media containing various levels of GuHCl or 2CMC as a control. Cells were incubated at 37°C in 5% CO₂ for 3 days. The effect of GuHCl treatment on HuNoV replicon RNA was then evaluated by qRT-PCR as described (21) and western blot using rabbit polyclonal antisera to norovirus NS3. In addition, the effect of GuHCl on cell viability was determined using CellTiter-Blue (Promega) according to the manufacturer's instructions.

ACKNOWLEDGMENTS

We thank Dr. Linqing Zhao (Beijing, China) for generously providing reagents, and Drs. Linqing Zhao and Huimin Yan (Wuhan, China) for helpful discussions.

This work was supported by the National Natural Science Foundation of China (NSFC) - Excellent Young Scientists Fund (grant No. 31522004 to X.Z.), the Newton Advanced Fellowship from the UK Academy of Medical Sciences and NSFC (No. 3161101464 to X.Z. and S.C.), the NSFC grant No. 31670161 (to X.Z.), the Strategic Priority Research Program of Chinese Academy of Sciences (No. XDPB0301 to X.Z.), the National High-Tech R&D Program of China (863 Program;

grant No. 2015AA020939 to X.Z.), the National Basic Research Program of China (973 Program; grant No. 2014CB542603 to X.Z.), and the Distinguished Young Scientists Fund of Hubei Province (grant No. 2016CFA045 to X.Z.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. **Alhatlani, B., S. Vashist, and I. Goodfellow.** 2015. Functions of the 5' and 3' ends of calicivirus genomes. *Virus Res* **206**:134-143.
2. **Arias, A., E. Emmott, S. Vashist, and I. Goodfellow.** 2013. Progress towards the prevention and treatment of norovirus infections. *Future Microbiol* **8**:1475-1487.
3. **Bleichert, F., and S. J. Baserga.** 2007. The long unwinding road of RNA helicases. *Molecular cell* **27**:339-352.
4. **Bull, R. A., M. M. Tanaka, and P. A. White.** 2007. Norovirus recombination. *J Gen Virol* **88**:3347-3359.
5. **Bystroff, C., and Y. Shao.** 2002. Fully automated ab initio protein structure prediction using I-SITES, HMMSTR and ROSETTA. *Bioinformatics* **18 Suppl 1**:S54-61.
6. **Caliguiri, L. A., and I. Tamm.** 1968. Action of guanidine on the replication of poliovirus RNA. *Virology* **35**:408-417.
7. **Chang, K. O., S. V. Sosnovtsev, G. Belliot, A. D. King, and K. Y. Green.** 2006. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. *Virology* **353**:463-473.
8. **Chen, D., and J. T. Patton.** 1998. Rotavirus RNA replication requires a single-stranded 3' end for efficient minus-strand synthesis. *J Virol* **72**:7387-7396.
9. **Cheng, Z., J. Yang, H. Xia, Y. Qiu, Z. Wang, Y. Han, X. Xia, C. F. Qin, Y. Hu, and X. Zhou.** 2013. The nonstructural protein 2C of a Picorna-like virus displays nucleic acid helix destabilizing activity that can be functionally separated from its ATPase activity. *J Virol* **87**:5205-5218.
10. **Collaco, R. F., V. Kalman-Maltese, A. D. Smith, J. D. Dignam, and J. P. Trempe.** 2003. A biochemical characterization of the adeno-associated virus Rep40 helicase. *The Journal of biological chemistry* **278**:34011-34017.
11. **Cotton, B. T., J. L. Hyde, S. T. Sarvestani, S. V. Sosnovtsev, K. Y. Green, P. A. White, and J. M. Mackenzie.** 2017. The Norovirus NS3 Protein Is a Dynamic Lipid- and Microtubule-Associated Protein Involved in Viral RNA Replication. *J Virol* **91**.
12. **DeStefano, J. J., and O. Titilope.** 2006. Poliovirus protein 3AB displays nucleic acid chaperone and helix-destabilizing activities. *J Virol* **80**:1662-1671.
13. **Eden, J. S., M. M. Tanaka, M. F. Boni, W. D. Rawlinson, and P. A. White.** 2013. Recombination within the pandemic norovirus GII.4 lineage. *J Virol* **87**:6270-6282.
14. **Fankhauser, R. L., J. S. Noel, S. S. Monroe, T. Ando, and R. I. Glass.** 1998. Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. *J Infect Dis* **178**:1571-1578.
15. **Frick, D. N.** 2007. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. *Curr*

Issues Mol Biol **9**:1-20.

16. **Fukushi, S., S. Kojima, R. Takai, F. B. Hoshino, T. Oka, N. Takeda, K. Katayama, and T. Kageyama.** 2004. Poly(A)- and Primer-Independent RNA Polymerase of Norovirus. *Journal of Virology* **78**:3889-3896.
17. **Grohman, J. K., R. J. Gorelick, C. R. Lickwar, J. D. Lieb, B. D. Bower, B. M. Znosko, and K. M. Weeks.** 2013. A guanosine-centric mechanism for RNA chaperone function. *Science* **340**:190-195.
18. **Hahn, C. S., Y. S. Hahn, C. M. Rice, E. Lee, L. Dalgarno, E. G. Strauss, and J. H. Strauss.** 1987. Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. *J Mol Biol* **198**:33-41.
19. **Jarmoskaite, I., and R. Russell.** 2014. RNA helicase proteins as chaperones and remodelers. *Annual review of biochemistry* **83**:697-725.
20. **Kadare, G., and A. L. Haenni.** 1997. Virus-encoded RNA helicases. *J Virol* **71**:2583-2590.
21. **Kageyama, T., S. Kojima, M. Shinohara, K. Uchida, S. Fukushi, F. B. Hoshino, N. Takeda, and K. Katayama.** 2003. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. *J Clin Microbiol* **41**:1548-1557.
22. **Karpe, Y. A., P. P. Aher, and K. S. Lole.** 2011. NTPase and 5'-RNA triphosphatase activities of Chikungunya virus nsP2 protein. *PLoS One* **6**:e22336.
23. **Karst, S. M.** 2010. Pathogenesis of noroviruses, emerging RNA viruses. *Viruses* **2**:748-781.
24. **Karst, S. M., C. E. Wobus, I. G. Goodfellow, K. Y. Green, and H. W. Virgin.** 2014. Advances in norovirus biology. *Cell Host Microbe* **15**:668-680.
25. **Kaufman, S. S., K. Y. Green, and B. E. Korba.** 2014. Treatment of norovirus infections: moving antivirals from the bench to the bedside. *Antiviral Res* **105**:80-91.
26. **Kwong, A. D., B. G. Rao, and K. T. Jeang.** 2005. Viral and cellular RNA helicases as antiviral targets. *Nature reviews. Drug discovery* **4**:845-853.
27. **Labois, C. L., C. Augeron, M. H. Couturier-Turpin, C. Gespach, A. M. Cheret, and F. Potet.** 1982. Characterization of a newly established human gastric cancer cell line HGT-1 bearing histamine H2-receptors. *Cancer Res* **42**:1541-1548.
28. **Lam, A. M., and D. N. Frick.** 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. *J Virol* **80**:404-411.
29. **Lee, N. R., H. M. Kwon, K. Park, S. Oh, Y. J. Jeong, and D. E. Kim.** 2010. Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13. *Nucleic Acids Res* **38**:7626-7636.
30. **Leen, E. N., F. Sorgeloos, S. Correia, Y. Chaudhry, F. Cannac, C. Pastore, Y. Xu, S. C. Graham, S. J. Matthews, I. G. Goodfellow, and S. Curry.** 2016. A Conserved Interaction between a C-Terminal Motif in Norovirus VPg and the HEAT-1 Domain of eIF4G Is Essential for Translation Initiation. *PLoS Pathog* **12**:e1005379.
31. **Li, D., R. Zhao, W. Lilyestrom, D. Gai, R. Zhang, J. A. DeCaprio, E. Fanning, A. Jochimiak, G. Szakonyi, and X. S. Chen.** 2003. Structure of the replicative helicase of the oncoprotein SV40 large tumour antigen. *Nature* **423**:512-518.

32. **Lin, B. Y., A. M. Makhov, J. D. Griffith, T. R. Broker, and L. T. Chow.** 2002. Chaperone Proteins Abrogate Inhibition of the Human Papillomavirus (HPV) E1 Replicative Helicase by the HPV E2 Protein. *Molecular and Cellular Biology* **22**:6592-6604.
33. **Lin, X., L. Thorne, Z. Jin, L. A. Hammad, S. Li, J. Deval, I. G. Goodfellow, and C. C. Kao.** 2015. Subgenomic promoter recognition by the norovirus RNA-dependent RNA polymerases. *Nucleic Acids Res* **43**:446-460.
34. **Loddo, B., W. Ferrari, G. Brotzu, and A. Spanedda.** 1962. In vitro inhibition of infectivity of polio viruses by guanidine. *Nature* **193**:97-98.
35. **Loddo, B., S. Muntoni, A. Spanedda, G. Brotzu, and W. Ferrari.** 1963. Guanidine conditioned infectivity of ribonucleic acid extracted from a strain of guanidine-dependent polio-1-virus. *Nature* **197**:315.
36. **Lopez-Manriquez, E., S. Vashist, L. Urena, I. Goodfellow, P. Chavez, J. E. Mora-Heredia, C. Cancio-Lonches, E. Garrido, and A. L. Gutierrez-Escolano.** 2013. Norovirus genome circularization and efficient replication are facilitated by binding of PCBP2 and hnRNP A1. *J Virol* **87**:11371-11387.
37. **Lorsch, J. R.** 2002. RNA chaperones exist and DEAD box proteins get a life. *Cell* **109**:797-800.
38. **Lyons, T., K. E. Murray, A. W. Roberts, and D. J. Barton.** 2001. Poliovirus 5'-terminal cloverleaf RNA is required in cis for VPg uridylation and the initiation of negative-strand RNA synthesis. *J Virol* **75**:10696-10708.
39. **McFadden, N., A. Arias, I. Dry, D. Bailey, J. Witteveltdt, D. J. Evans, I. Goodfellow, and P. Simmonds.** 2013. Influence of genome-scale RNA structure disruption on the replication of murine norovirus--similar replication kinetics in cell culture but attenuation of viral fitness in vivo. *Nucleic Acids Res* **41**:6316-6331.
40. **McFadden, N., D. Bailey, G. Carrara, A. Benson, Y. Chaudhry, A. Shortland, J. Heeney, F. Yarovinsky, P. Simmonds, A. Macdonald, and I. Goodfellow.** 2011. Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4. *PLoS Pathog* **7**:e1002413.
41. **Musier-Forsyth, K.** 2010. RNA remodeling by chaperones and helicases. *RNA Biol* **7**:632-633.
42. **O, S. J., and K. W. Kim.** 1973. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. *Neurology* **23**:1084-1090.
43. **Oh, S. J., Y. W. Lee, and E. Rutsky.** 1977. Eaton-Lambert syndrome: reflex improvement with guanidine. *Arch Phys Med Rehabil* **58**:457-459.
44. **Pfister, T., and E. Wimmer.** 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. *The Journal of biological chemistry* **274**:6992-7001.
45. **Pfister, T., and E. Wimmer.** 2001. Polypeptide p41 of a Norwalk-like virus is a nucleic acid-independent nucleoside triphosphatase. *J Virol* **75**:1611-1619.
46. **Pincus, S. E., D. C. Diamond, E. A. Emini, and E. Wimmer.** 1986. Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. *J Virol* **57**:638-646.
47. **Rajkowitsch, L., D. Chen, S. Stampfl, K. Semrad, C. Waldsich, O. Mayer, M. F. Jantsch, R. Konrat, U. Blasi, and R. Schroeder.** 2007. RNA chaperones, RNA annealers and RNA helicases. *RNA Biol* **4**:118-130.
48. **Raju, R., and D. Kolakofsky.** 1989. The ends of La Crosse virus genome and antigenome RNAs within

nucleocapsids are base paired. J Virol **63**:122-128.

49. **Rocha-Pereira, J., D. Jochmans, K. Dallmeier, P. Leyssen, R. Cunha, I. Costa, M. S. Nascimento, and J. Neyts.** 2012. Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. Biochemical and biophysical research communications **427**:796-800.
50. **Rocha-Pereira, J., D. Jochmans, Y. Debing, E. Verbeken, M. S. Nascimento, and J. Neyts.** 2013. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol **87**:11798-11805.
51. **Saczewski, F., and L. Balewski.** 2009. Biological activities of guanidine compounds. Expert Opin Ther Pat **19**:1417-1448.
52. **Saczewski, F., and L. Balewski.** 2013. Biological activities of guanidine compounds, 2008 - 2012 update. Expert Opin Ther Pat **23**:965-995.
53. **Steil, B. P., and D. J. Barton.** 2009. Conversion of VPg into VPgpUpUOH before and during poliovirus negative-strand RNA synthesis. J Virol **83**:12660-12670.
54. **Thorne, L., D. Bailey, and I. Goodfellow.** 2012. High-resolution functional profiling of the norovirus genome. J Virol **86**:11441-11456.
55. **Tortorici, M. A., B. A. Shapiro, and J. T. Patton.** 2006. A base-specific recognition signal in the 5' consensus sequence of rotavirus plus-strand RNAs promotes replication of the double-stranded RNA genome segments. RNA **12**:133-146.
56. **Vinje, J.** 2015. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol **53**:373-381.
57. **Wang, Q., Y. Han, Y. Qiu, S. Zhang, F. Tang, Y. Wang, J. Zhang, Y. Hu, and X. Zhou.** 2012. Identification and characterization of RNA duplex unwinding and ATPase activities of an alphatetravirus superfamily 1 helicase. Virology **433**:440-448.
58. **Wang, Z., D. Wu, Y. Liu, X. Xia, W. Gong, Y. Qiu, J. Yang, Y. Zheng, J. Li, Y. F. Wang, Y. Xiang, Y. Hu, and X. Zhou.** 2015. Drosophila Dicer-2 has an RNA interference-independent function that modulates Toll immune signaling. Sci Adv **1**:e1500228.
59. **Xia, H., P. Wang, G. C. Wang, J. Yang, X. Sun, W. Wu, Y. Qiu, T. Shu, X. Zhao, L. Yin, C. F. Qin, Y. Hu, and X. Zhou.** 2015. Human Enterovirus Nonstructural Protein 2CATPase Functions as Both an RNA Helicase and ATP-Independent RNA Chaperone. PLoS Pathog **11**:e1005067.
60. **Yang, J., Z. Cheng, S. Zhang, W. Xiong, H. Xia, Y. Qiu, Z. Wang, F. Wu, C. F. Qin, L. Yin, Y. Hu, and X. Zhou.** 2014. A cypovirus VP5 displays the RNA chaperone-like activity that destabilizes RNA helices and accelerates strand annealing. Nucleic Acids Res **42**:2538-2554.
61. **Yang, J., H. Xia, Q. Qian, and X. Zhou.** 2015. RNA chaperones encoded by RNA viruses. Virologica Sinica **30**:401-409.
62. **Yunus, M. A., X. Lin, D. Bailey, I. Karakasiliotis, Y. Chaudhry, S. Vashist, G. Zhang, L. Thorne, C. C. Kao, and I. Goodfellow.** 2015. The murine norovirus core subgenomic RNA promoter consists of a stable stem-loop that can direct accurate initiation of RNA synthesis. J Virol **89**:1218-1229.
63. **Zarate-Perez, F., M. Bardelli, J. W. Burgner, 2nd, M. Villamil-Jarauta, K. Das, D. Kekilli, J. Mansilla-Soto, R. M. Linden, and C. R. Escalante.** 2012. The interdomain linker of AAV-2 Rep68 is an

integral part of its oligomerization domain: role of a conserved SF3 helicase residue in oligomerization. PLoS Pathog **8**:e1002764.

64. **Zheng, D. P., T. Ando, R. L. Fankhauser, R. S. Beard, R. I. Glass, and S. S. Monroe.** 2006. Norovirus classification and proposed strain nomenclature. Virology **346**:312-323.
65. **Zuniga, S., I. Sola, J. L. Cruz, and L. Enjuanes.** 2009. Role of RNA chaperones in virus replication. Virus Res **139**:253-266.

FIGURE LEGENDS

Fig. 1. Norovirus NS3 is similar with other virus-encoded SF3 helicases in consensus motifs and protein structures. (A) The genomic RNA of norovirus is depicted, which contains three ORFs (1, 2, and 3). The 5' proximal ORF1 encodes a polyprotein that is subsequently self-cleaved into six nonstructural proteins (NS1/2, NS3, NS4, NS5/VPg, NS6^{Pro}, and NS7/RdRP) by viral protease NS6^{Pro}. The ORF2 and ORF3 encode structural proteins VP1 and VP2, respectively. (B) Sequence alignments of the helicase core domains of NV NS3 and other SF3 viral helicases, including EV71 2C^{ATPase}, SV40 LTag, HPV18 E1, and AAV2 Rep40. The SF3 consensus motifs A, B, and C were indicated. (C) The structure of NV NS3 without its N-terminal domain (NS3ΔN) was predicted by the HMMSTR/Rosetta server. NS3ΔN containing the middle helicase core (HC) domain and the C-terminal domain (CTD) is shown in green. The SF3 motifs A, B, and C are indicated and highlighted in red. (D-F) Structural alignments of NV NS3ΔN (green) and SV40 LTag, HPV18E1, or AAV2 Rep40 (cyan). The N-terminal domain of E2 binding to HPV18 E1 is shown in brown. The SF3 motifs A, B, and C of these viral helicases are highlighted in blue.

Fig. 2. NV NS3 has NTPase activity. (A) MBP-NS3 was reacted with the indicated NTP. The NTPase activity was measured as nanomoles of released inorganic phosphate. (B-D) The NTPase activity of MBP-NS3 was determined at the indicated concentrations of ATP (B), at the indicated concentrations of Mg²⁺ (C), or at the indicated pH (D). For (B and C), the MBP alone was used as the negative control. For (A-D), error bars represent standard deviation (SD) values from three separate experiments.

Fig. 3. NV NS3 has nucleic acid helix unwinding activity. (A) The standard RNA/RNA helix (R*/R substrate) is illustrated in the upper panel. 0.1 pmol R*/R substrate was reacted with 20 pmol each indicated protein. Non-boiled reaction mixture (lane 1) and the reaction mixture with MBP alone (lane 3) were used as negative controls, boiled reaction mixture (lane 2) and the reaction mixture with purified MBP-fusion EV71 2C^{ATPase} (lane 5) were used as positive controls. (B-D) DNA/DNA helix (D*/D substrate), DNA/RNA hybrid helix (D*/R), and RNA/DNA hybrid helix (R*/D) are illustrated in each upper panel. 0.1 pmol of each indicated substrate was reacted with 20 pmol each indicated protein. For (B-D), lane 1, non-boiled reaction mixture; lane 2, boiled reaction mixture; lane 3, reaction mixture with purified MBP-fusion NS3; lane 4, reaction mixture with purified MBP-fusion EV71 2C^{ATPase}. The helix unwinding was detected via gel electrophoresis and scanning on a Typhoon 9500 imager. Asterisks indicate the HEX-labeled strands.

Fig. 4. Biochemical characterization of RNA helix unwinding activity of NV NS3. (A) Illustration of the standard RNA helix (R*/R) substrate. (B-D) 0.1 pmol R*/R substrate was reacted with 20 pmol MBP-NS3 in the absence or presence of individual NTP (B), increasing concentrations of Mg²⁺ (C), or different pH values (D) as indicated. Non-boiled (lane 1) or boiled (lane 2) reaction mixture was used as negative or positive control. Asterisks indicate the HEX-labeled strands. The helix unwinding activity was detected via gel electrophoresis and scanning on a Typhoon 9500 imager.

Fig. 5. NV NS3 unwinds RNA helix in a bidirectional manner. (A and B) Schematic illustration of the RNA helix substrate with the 5' single-stranded protrusion (A) or 3' single-stranded protrusion (B). Asterisks indicate the HEX-labeled strands. (C) MBP-NS3 (20 pmol) was incubated with 5' single-stranded protruded (lane 3) or 3' single-stranded protruded (lane 6) RNA helix substrate (0.1 pmol). Non-boiled (lanes 1 and 4) or boiled reaction mixtures (lanes 2 and 5) were used as negative or positive controls. (D and E) MBP-NS3 (20 pmol) was reacted with 5'-protruded (D) or 3'-protruded RNA helix substrate (E) in the presence of indicated concentrations of ATP. The helix unwinding was detected as described in Fig. 3.

Fig. 6. The SF3 motif A is critical for the helicase activity of NV NS3. (A) Amino acids sequence alignment of NV NS3, SHV NS3, and MNV NS3. The SF3 consensus motifs A, B, and C were indicated. (B) The standard RNA helix (R*/R) substrate (0.1 pmol) was reacted with 20 pmol wild-type (WT) (lane 4), GK168AA (lane 5), or GK168AA-DD212AA (lane 6) MBP-NS3. Non-boiled reaction mixture (lane 1) and the reaction mixture with MBP alone addition (lane 3) were used as negative controls; the boiled reaction mixture (lane 2) was used as positive control. (C) The standard RNA helix (R*/R) substrate (0.1 pmol) was reacted with 20 pmol GK168AA mutant MBP-NS3 in the presence of indicated concentrations of ATP. For (B and C), asterisks indicate the HEX-labeled strands.


Fig. 7. NV NS3 has RNA chaperoning activity to destabilize structured RNA strands and promote annealing. (A) The standard RNA helix (R*/R) substrate (0.1 pmol) was reacted with 20 pmol MBP-NS3 in the absence or presence of 5 mM ATP or ATP analog (AMP-PNP) as indicated. Lane 1, non-boiled reaction mixture; lane 2, boiled reaction mixture; lane 3, the reaction mixture with MBP-NS3 in the absence of ATP; lanes 4-5, the reaction mixture with MBP-NS3 in the presence of AMP-PNP or ATP. (B) Schematic illustrations of the stem-loop structures of the two complementary 42-nt RNA strands. Asterisk indicates the HEX-labeled strand. (C) The two strands were 1:1 mixed (0.1 pmol each) and reacted with indicated amount of MBP-NS3. (D) The hybridization assay as in (C) was conducted in the absence (lanes 3-6) or presence (lanes 7-10) of 20 pmol MBP-NS3 for indicated reaction times. For (C and D), the pre-annealed (lane 1) or boiled (lane 2) strands were used as positive or negative control, respectively. The hybridized and free strands are indicated.

Fig. 8. NV NS3 facilitates noroviral RNA synthesis *in vitro*. (A) Schematic illustration of the experimental procedures. (B and D) The *in vitro* transcribed NV 3'-end 1-400 nts of (-)-vRNA template was incubated with 10 pmol recombinant NS7/RdRP and NTP mix in the absence or presence of 10 pmol MBP-NS3 (B) or MBP-NS3_{GK168AA} (D) at 30 °C for 30, 60 or 90 min as indicated. The reaction products were detected by Northern blots. (C and E) The synthesized (+)-RNA products in (B and D) were quantified via Bio-Rad Quantity One software. The relative RNA production was determined by comparing the level of RNA products in presence of MBP-NS3 at each indicated time point with that in the absence of NS3 at 30 min (lane 2). The error bars represent SD values from three separate experiments.

Fig. 9. GuHCl inhibits the biochemical activities of NV NS3. (A) The NTPase activity of MBP-NS3 was measured as nanomoles of released inorganic phosphate in the presence of indicated concentrations (0-10 mM) of GuHCl. MBP alone was used as the negative control. (B) The standard RNA helix (R*/R) substrate is illustrated in the upper panel. 0.1 pmol R*/R substrate was reacted with 20 pmol MBP-NS3 in the presence of indicated concentrations (0-10 mM) of GuHCl. Native (lane 1) or boiled (lane 2) reaction mixture was used as negative or positive control, respectively. The helix unwinding was detected via gel electrophoresis and scanning on a Typhoon 9500 imager. Asterisk indicates the HEX-labeled strand. (C) The unwinding activities under different GuHCl concentrations were plotted as a percentage of the released RNA from the total RNA helix substrate (Y-axis) at each indicated GuHCl concentration (X-axis) via Bio-Rad Quantity One software. The error bars represent standard deviation values from three separate experiments. (D) The two strands in Fig. 7B were 1:1 mixed (0.1 pmol each) and reacted with 10 pmol MBP-NS3 for 30 min in presence of different concentrations of GuHCl in the absence of NTP. The hybridization of the two strand was detected via gel electrophoresis and scanning on a Typhoon 9500 imager. The pre-annealed (lane 1) or boiled (lane 2) reaction mixture was used as positive or negative control, respectively. The hybridized and free strands are indicated. (E) The effect of GuHCl or 2-CMC on Norwalk virus RNA levels was determined by examining the impact on NV replicon RNA levels in HGT-NV cells following 3 days of treatment. HGT-NV cells were treated with the indicated levels of either GuHCl or 2-CMC and the levels of viral RNA calculated as a percentage of mock-treated control. (F) HGT-NV cells were treated as in (D) and the number of viable cells were determined. The cell viability was calculated as a percentage of mock-treated control. The error bars represent SD ($n=3$). Statistical significance was determined using an unpaired t-test. The experiment was repeated at least two independent times, with one representative data set presented.

Figure 1


A




B

	Motif A	Motif B	Motif C
NV NS3	GPPGI GKTAAEHLAKRLANEI RPPGKVG LVPREAVDHW- -	DGYHGEEV MLWDDYGM I KI	----- QEDCNKLQA- - - I A- DSAPLTLNCDRI ENKGMQFVS DAI VI TTN
EV71 2C	GSPGTGKSLATGI I ARAI ADKYHSS- V- - YSLPPDP DHF- -	DGYKQQV VMVMDDL CQNP D	----- GKDI SLFCQ- - - NV- STVDFI PPMASLEEKGV SFTSKF VI ASTN
SV40 LTag	GPI DSGKTTLAAALLELCGGKALN- - - - -	VNLPLDRLNFELGVAI DQFLVVFEDVKGTGG	ESRDLP SGQGI NNLD- NLRDYL DGS VKVNLE- KKHLNKR TQIFP- PGI VTMN
HPV18 E1	GPANTGKS YFGMSFI HFI QGAVI S- - - - -	FVNS- - TSHFWLEPLTDTKVAMLDDATTTC-	----- WTYFDTYMRNALD- GNPI SI D- RKHKP- LIQLKCPPI LL TTN
AAV2 Rep40	GPATTGKTNI AEAI AHTVP- - - FY- - - -	GCVNWTNENFPFND CVDKMI WEEGKMTAK	VVE- - - - - SAKAI L- GGSKVRVD- QKCK- SSAQIDPTPVI VTSN


C



D



E



F






Figure 2


A



B



C



D




Figure 3




Figure 4




Figure 5





Figure 6

A

NV_NS3	GFEDLARDLVVILGGIGLAIGFTRDKVSKMMKNAVDGIRAAQTQIGQYGLDHSLLKKYFFGGDQTEKTAKDIPSAVID	79
SHV_NS3	GFEDLARDLVVILGGIGLAIGFTRDKVTKVMKSAVDGIRAAQTQIGQYGLDHSLLKKYFFGGDQTERTKGIDPRAVID	79
MNV_NS3	GFEDLARDLVVETLLGGIGMAFGITSETIGRKLASTNSAIKAAQEMGKFAIEVVKQIMAWIWPSEIPVPALLSNMBCAIIK	80
Consensus	gp dla d vp lggig a g t l aa g e f d l e a i	
NV_NS3	MEVLSSSVTQLVREKQ SARAYMAILDNEEKAARKLSVRNADPHVSSTNALISRISMARALAKAQAEMTSRMRPVVIM	159
SHV_NS3	MEVLSSSVTQLVREKQAAKAYMNIIDNEEKAARKLSAKNADPHVISSTNALISRISMARSALAKAQAEMTSRMRPVVIM	159
MNV_NS3	NECQLENQLTAMLRIRNAGAEFLRSLEEDQEVKIAAKCGNSATTGTNAILARISMARAFKARAEQTSRVRPVVIM	160
Consensus	e t rd ld ee rk tpal rismar a ka ae tsr rpvvim	
NV_NS3	MCGEPGIGKTKAAEELAKRIANEIRPGGRVGLVPREAVDHWGYYEGEEVMLWDDYGMTKIQEDCNKLCIAIAISAEITLNC	239
SHV_NS3	MCGEPGIGKTKAAEELAKRIANEIRPGGRVGLVPREAVDHWGYYEGEEVMLWDDYGMTKILDDCNKLCIAIAISAEITLNC	239
MNV_NS3	VSGEPGIGKTCFCQNLAKRIASLGDETSVGIIIPRADVDHWDAYRGARVVLWDDFGMDNVVKIALRLQMLAITCEVILNC	240
Consensus	g pgigkt lakr a vg pr vdhw d y g v lwdd gm d lq ad p tlnc	
NV_NS3	DRIENKGMQFVSDAIVITTNAPGEAFVDFVNLGFVCRVDFLVYCTAEVEHTRKVSFGDTTALKDCFKLDSHLMKELA	319
SHV_NS3	DRIENKGMQFVSDAIVITTNAPGEAFVDFVNLGFVCRVDFLVYCTAEVEHTRKVSFGDTTALKDCFKLDSHLMKELA	319
MNV_NS3	DRIENKGMQFVSDAIVITTNAPGEAFVDFVNLGFVCRVDFLVYCTAEVEHTRKVSFGDTTALKDCFKLDSHLMKELA	320
Consensus	drienkg f s i ittn p p d vnl vcrr dflvy p v r pgd a k d sh la	
NV_NS3	PQGGFDNQGNTEFGKGVMPPTTINRLIQAVALTMERQDEEGL	362
SHV_NS3	PQGGFDNQGNTEFGKGVMPPTTINRLIQAVALTMERQDEEGL	362
MNV_NS3	PQGGFDNQGNTEFGKGVMPPTTINRLIQAVALTMERQDEEGL	363
Consensus	pqggfd qgn t p g k g k l aval er d f l	

B



C




Figure 7






Figure 8


A




B



D



C



E




Figure 9

